| abstract |
This application applies to TSC1 or TSC2, and VHL, RBI, PBRIM1, K.DM6A, RET, SETD2 ARID 1 A, BAP1, BRCA2, TP53, RBI, ATRX, FLT1, NTRK1, TLX3, KDM6A, CDH4, CDKN2C, DAXX, ERBB3 , based on the mutation status of one of GNAS, IL7R, PDGFRB, PMS2, PTEN, SMARCA4 and YY1AP1, cancer by administering a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug) and a carrier protein (such as albumin) Provided are methods and compositions for treating |